Clinical trials with molecules targeting aberrant receptor tyrosine kinase activation or immunotherapy targeting immune checkpoint molecules, including programmed death-ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1), have shown promising results for improving the life expectancy of patients with malignant tumors [23,24,25,26]. The gene discussed is NTRK1; the disease is cancer.